Sanofi SNY

Treatment for a serious lung disease failed to meet the company’s primary goal.

Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) reported third quarter fiscal 2026 financial results on Monday, with revenue of $673.1 million, up significantly from $7.9 million in the same quarter last year. The company posted adjusted earnings per share of $4.73, compared to a loss of -$1.03 per share in the prior-year period. Shares are down 2% in after hours trading following the earnings release, though they were up nearly 8% shortly after.

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,415,546,786Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.

New digital leadership at Vallourec Vallourec (ENXTPA:VK) has appointed Isabelle Quéméneur as Group Chief Digital and Information Officer, adding her to the Executive Committee as of 5 October 2026 after senior technology roles at Danone. The move puts a seasoned technologist with experience across Société Générale, AXA and Sanofi in charge of the group’s digital and information agenda, an area many investors now track alongside more traditional financial metrics. Vallourec’s share price has...

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

At Veeva R&D and Quality Summit on October 20-21 in Boston, Veeva Systems (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, CROs, and sites — including Duke University, Eli Lilly and Company, Pfizer, Sanofi, Tolmar, UCB, and the University of Pennsylvania — to explain how they are driving new ways of working across drug development and quality.

European equities traded in the US as American depositary receipts fell late Wednesday morning with

Report Forecasts Plozasiran Sales Through 2034 Across Severe Hypertriglyceridemia, Familial Chylomicronemia Syndrome and Mixed Hyperlipidemia, Following Sanofi's Greater China Licensing DealDublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Plozasiran Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Research and Markets has published Plozasiran Sales Forecast and Market Size Analysis - 2034, a report released in April 2026. The report assesses the comm

In early October 2026, Regeneron Pharmaceuticals reported new clinical data across oncology and obesity programs and expanded its long-running antibody alliance with Sanofi, which includes US$1.00 billion upfront and potential future milestone payments worth up to US$7.00 billion. These updates highlight Regeneron’s attempt to broaden its pipeline beyond current blockbusters, particularly through ubamatamab in low-grade serous ovarian cancer and next-generation long-acting immunology...

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q3 2026 results will be published on October 30, 2026. About Sanofi Sanofi is a

(OTC PINK:VICP) ("VICP" or the "Company") today announced that FutureBrand, the global brand consultancy behind the corporate identities of Sanofi, GSK and Merck, has onboarded the Company as a client through its Latin America practice and delivered a new corporate identity for Vicapsys Life Sciences and its wholly owned subsidiary, of Puerto Rico, Inc. The rollout of the new identity is the first in a series of corporate housekeeping steps the Company is completing following its reverse merger

Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.

Regeneron announces an expanded deal with Sanofi. Here’s what the disclosure really means for REGN shares.

Sanofi has partnered with 2026 NBA Champion Karl-Anthony Towns to help raise awareness about the importance of COVID-19 vaccination among those eligible during the respiratory season. Through a series of digital and social media activations, Towns will share his personal perspective on the impact COVID-19 had on his life and family, why protecting his health remains a priority, and encourage people to have informed conversations with their healthcare providers about COVID-19 vaccination options,

European equities traded in the US as American depositary receipts were trending higher late Friday